RiverVest Venture Management’s Xilio Therapeutics XLO Stock Holding History

RiverVest Venture Management’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.14M	Hold	102,960	–	–	16.6%	3
2024 Q2	$1.37M	Hold	102,960	–	–	20.01%	3
2024 Q1	$1.56M	Hold	102,960	–	–	19.12%	3
2023 Q4	$793K	Hold	102,960	–	–	2.92%	4
2023 Q3	$3.04M	Hold	102,960	–	–	7.52%	4
2023 Q2	$3.78M	Hold	102,960	–	–	4.19%	5
2023 Q1	$4.57M	Hold	102,960	–	–	5.29%	5
2022 Q4	$3.88M	Hold	102,960	–	–	4.52%	4
2022 Q3	$4.2M	Hold	102,960	–	–	4.87%	4
2022 Q2	$4.21M	Hold	102,960	–	–	6.19%	4
2022 Q1	$10.2M	Hold	102,960	–	–	10.46%	3
2021 Q4	$23.1M	Buy	+102,960	New	+$24.6M	16.45%	3

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

RiverVest Venture Management's XLO Position: Q3 2024 in Review

RiverVest Venture Management held its Xilio Therapeutics (XLO) position steady in Q3 2024 at 102,960 shares worth $1.14M. The position accounts for 16.6% of the portfolio, ranked #3.

RiverVest Venture Management first reported a position in XLO in Q4 2021 and has held it in 12 quarters since. The position peaked at $23.1M in Q4 2021. 33 funds tracked by Wall St. Rank hold XLO as of Q3 2024.

RiverVest Venture Management held 102,960 shares of Xilio Therapeutics worth $1.14M as of Q3 2024.
RiverVest Venture Management left its Xilio Therapeutics share count unchanged in Q3 2024.
Xilio Therapeutics made up 16.6% of RiverVest Venture Management's portfolio in Q3 2024, its #3 holding.
RiverVest Venture Management first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 12 quarters since.
RiverVest Venture Management's Xilio Therapeutics position peaked at $23.1M in Q4 2021.
33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2024.

Based on RiverVest Venture Management's 13F filing for Q3 2024, filed 30 Oct 2024.